The Requirement for Cyclin D Function in Tumor Maintenance

Cancer Cell

Volumn 22, Issue 4, 2012, Pages 438-451

  Choi, Yoon Jong ^a,d   Li, Xiaoyu ^a,d   Hydbring, Per ^a,d   Sanda, Takaomi ^a,c,d   Stefano, Joanna ^a   Christie, Amanda L ^a   Signoretti, Sabina ^a,b   Look, A Thomas ^a,c,d   Kung, Andrew L ^a,d   von Boehmer, Harald ^a,d   Sicinski, Piotr ^a,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN D3; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NOTCH1 RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER THERAPY; CONTROLLED STUDY; FEMALE; LEUKEMIA CELL; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN TARGETING; SENESCENCE; T LYMPHOCYTE; TUMOR CELL;

EID: 84867618851     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.09.015     Document Type: Article

References (52)

1. Anders L., Ke N., Hydbring P., Choi Y.J., Widlund H.R., Chick J.M., Zhai H., Vidal M., Gygi S.P., Braun P., Sicinski P. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 2011, 20:620-634.
2. Beroukhim R., Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., Barretina J., Boehm J.S., Dobson J., Urashima M., et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463:899-905.
3. Bodrug S.E., Warner B.J., Bath M.L., Lindeman G.J., Harris A.W., Adams J.M. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J. 1994, 13:2124-2130.
4. Bowe D.B., Kenney N.J., Adereth Y., Maroulakou I.G. Suppression of Neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin E. Oncogene 2002, 21:291-298.
5. Burns K.H., Agno J.E., Sicinski P., Matzuk M.M. Cyclin D2 and p27 are tissue-specific regulators of tumorigenesis in inhibin alpha knockout mice. Mol. Endocrinol. 2003, 17:2053-2069.
6. Chaganti R.S., Houldsworth J. Genetics and biology of adult human male germ cell tumors. Cancer Res. 2000, 60:1475-1482.
7. Chen D., Pacal M., Wenzel P., Knoepfler P.S., Leone G., Bremner R. Division and apoptosis of E2f-deficient retinal progenitors. Nature 2009, 462:925-929.
8. Chiang M.Y., Xu M.L., Histen G., Shestova O., Roy M., Nam Y., Blacklow S.C., Sacks D.B., Pear W.S., Aster J.C. Identification of a conserved negative regulatory sequence that influences the leukemogenic activity of NOTCH1. Mol. Cell. Biol. 2006, 26:6261-6271.
9. Chicas A., Wang X., Zhang C., McCurrach M., Zhao Z., Mert O., Dickins R.A., Narita M., Zhang M., Lowe S.W. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell 2010, 17:376-387.
10. Chong J.L., Wenzel P.L., Sáenz-Robles M.T., Nair V., Ferrey A., Hagan J.P., Gomez Y.M., Sharma N., Chen H.Z., Ouseph M., et al. E2f1-3 switch from activators in progenitor cells to repressors in differentiating cells. Nature 2009, 462:930-934.
11. Cooper A.B., Sawai C.M., Sicinska E., Powers S.E., Sicinski P., Clark M.R., Aifantis I. A unique function for cyclin D3 in early B cell development. Nat. Immunol. 2006, 7:489-497.
12. Dean J.L., Thangavel C., McClendon A.K., Reed C.A., Knudsen E.S. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene 2010, 29:4018-4032.
13. Deshpande A., Sicinski P., Hinds P.W. Cyclins and CDKs in development and cancer: a perspective. Oncogene 2005, 24:2909-2915.
14. Fantl V., Stamp G., Andrews A., Rosewell I., Dickson C. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev. 1995, 9:2364-2372.
15. Fry D.W., Harvey P.J., Keller P.R., Elliott W.L., Meade M., Trachet E., Albassam M., Zheng X., Leopold W.R., Pryer N.K., Toogood P.L. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 2004, 3:1427-1438.
16. Fu M., Wang C., Li Z., Sakamaki T., Pestell R.G. Minireview: cyclin D1: normal and abnormal functions. Endocrinology 2004, 145:5439-5447.
17. Hayashi S., McMahon A.P. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev. Biol. 2002, 244:305-318.
18. Hu M.G., Deshpande A., Enos M., Mao D., Hinds E.A., Hu G.F., Chang R., Guo Z., Dose M., Mao C., et al. A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis. Cancer Res. 2009, 69:810-818.
19. Hulit J., Wang C., Li Z., Albanese C., Rao M., Di Vizio D., Shah S., Byers S.W., Mahmood R., Augenlicht L.H., et al. Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice. Mol. Cell. Biol. 2004, 24:7598-7611.
20. Ianari A., Natale T., Calo E., Ferretti E., Alesse E., Screpanti I., Haigis K., Gulino A., Lees J.A. Proapoptotic function of the retinoblastoma tumor suppressor protein. Cancer Cell 2009, 15:184-194.
21. Kimbrel E.A., Davis T.N., Bradner J.E., Kung A.L. In vivo pharmacodynamic imaging of proteasome inhibition. Mol. Imaging 2009, 8:140-147.
22. Kühn R., Schwenk F., Aguet M., Rajewsky K. Inducible gene targeting in mice. Science 1995, 269:1427-1429.
23. Kuilman T., Peeper D.S. Senescence-messaging secretome: SMS-ing cellular stress. Nat. Rev. Cancer 2009, 9:81-94.
24. Landis M.W., Pawlyk B.S., Li T., Sicinski P., Hinds P.W. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 2006, 9:13-22.
25. Li S.K., Smith D.K., Leung W.Y., Cheung A.M., Lam E.W., Dimri G.P., Yao K.-M. FoxM1c counteracts oxidative stress-induced senescence and stimulates Bmi-1 expression. J. Biol. Chem. 2008, 283:16545-16553.
26. Li X., Gounari F., Protopopov A., Khazaie K., von Boehmer H. Oncogenesis of T-ALL and nonmalignant consequences of overexpressing intracellular NOTCH1. J. Exp. Med. 2008, 205:2851-2861.
27. Lin Y., Bloodgood B.L., Hauser J.L., Lapan A.D., Koon A.C., Kim T.K., Hu L.S., Malik A.N., Greenberg M.E. Activity-dependent regulation of inhibitory synapse development by Npas4. Nature 2008, 455:1198-1204.
28. Lovec H., Grzeschiczek A., Kowalski M.B., Möröy T. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J. 1994, 13:3487-3495.
29. Malumbres M., Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 2009, 9:153-166.
30. Muller W.J., Sinn E., Pattengale P.K., Wallace R., Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-Neu oncogene. Cell 1988, 54:105-115.
31. Musgrove E.A., Caldon C.E., Barraclough J., Stone A., Sutherland R.L. Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 2011, 11:558-572.
32. Narita M., Nünez S., Heard E., Narita M., Lin A.W., Hearn S.A., Spector D.L., Hannon G.J., Lowe S.W. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003, 113:703-716.
33. O'Neil J., Grim J., Strack P., Rao S., Tibbitts D., Winter C., Hardwick J., Welcker M., Meijerink J.P., Pieters R., et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J. Exp. Med. 2007, 204:1813-1824.
34. Park H.J., Carr J.R., Wang Z., Nogueira V., Hay N., Tyner A.L., Lau L.F., Costa R.H., Raychaudhuri P. FoxM1, a critical regulator of oxidative stress during oncogenesis. EMBO J. 2009, 28:2908-2918.
35. Puyol M., Martín A., Dubus P., Mulero F., Pizcueta P., Khan G., Guerra C., Santamaría D., Barbacid M. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010, 18:63-73.
36. Reddy H.K., Mettus R.V., Rane S.G., Graña X., Litvin J., Reddy E.P. Cyclin-dependent kinase 4 expression is essential for Neu-induced breast tumorigenesis. Cancer Res. 2005, 65:10174-10178.
37. Robles A.I., Rodriguez-Puebla M.L., Glick A.B., Trempus C., Hansen L., Sicinski P., Tennant R.W., Weinberg R.A., Yuspa S.H., Conti C.J. Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev. 1998, 12:2469-2474.
38. Ruas M., Gregory F., Jones R., Poolman R., Starborg M., Rowe J., Brookes S., Peters G. CDK4 and CDK6 delay senescence by kinase-dependent and p16INK4a-independent mechanisms. Mol. Cell. Biol. 2007, 27:4273-4282.
39. Sage J., Miller A.L., Pérez-Mancera P.A., Wysocki J.M., Jacks T. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 2003, 424:223-228.
40. Sherr C.J., Roberts J.M. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 2004, 18:2699-2711.
41. Sicinska E., Aifantis I., Le Cam L., Swat W., Borowski C., Yu Q., Ferrando A.A., Levin S.D., Geng Y., von Boehmer H., Sicinski P. Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell 2003, 4:451-461.
42. Sicinska E., Lee Y.M., Gits J., Shigematsu H., Yu Q., Rebel V.I., Geng Y., Marshall C.J., Akashi K., Dorfman D.M., et al. Essential role for cyclin D3 in granulocyte colony-stimulating factor-driven expansion of neutrophil granulocytes. Mol. Cell. Biol. 2006, 26:8052-8060.
43. Sicinski P., Donaher J.L., Parker S.B., Li T., Fazeli A., Gardner H., Haslam S.Z., Bronson R.T., Elledge S.J., Weinberg R.A. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 1995, 82:621-630.
44. Trimarchi J.M., Lees J.A. Sibling rivalry in the E2F family. Nat. Rev. Mol. Cell Biol. 2002, 3:11-20.
45. Tsikitis M., Zhang Z., Edelman W., Zagzag D., Kalpana G.V. Genetic ablation of Cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss. Proc. Natl. Acad. Sci. USA 2005, 102:12129-12134.
46. Wang T.C., Cardiff R.D., Zukerberg L., Lees E., Arnold A., Schmidt E.V. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994, 369:669-671.
47. Weng A.P., Ferrando A.A., Lee W., Morris J.P., Silverman L.B., Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306:269-271.
48. Weinstat-Saslow D., Merino M.J., Manrow R.E., Lawrence J.A., Bluth R.F., Wittenbel K.D., Simpson J.F., Page D.L., Steeg P.S. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat. Med. 1995, 1:1257-1260.
49. Young A.P., Longmore G.D. Differential regulation of apoptotic genes by Rb in human versus mouse cells. Oncogene 2004, 23:2587-2599.
50. Yu Q., Geng Y., Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001, 411:1017-1021.
51. Yu Q., Sicinska E., Geng Y., Ahnström M., Zagozdzon A., Kong Y., Gardner H., Kiyokawa H., Harris L.N., Stål O., Sicinski P. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 2006, 9:23-32.
52. Zhang Q., Sakamoto K., Liu C., Triplett A.A., Lin W.C., Rui H., Wagner K.U. Cyclin D3 compensates for the loss of cyclin D1 during ErbB2-induced mammary tumor initiation and progression. Cancer Res. 2011, 71:7513-7524.